BioPharma Drive: Drug Pricing

OCTOBER 23, 2023

The Swiss pharmaceutical company has agreed to buy Televant, a company set up by Roivant and Pfizer to develop a promising inflammatory bowel disease treatment.

Disease 65

Disease Pharmaceutical Companies Pharmaceuticals Treatment 65

Drug Target Review

AUGUST 6, 2024

Autoimmune diseases : Rheumatoid Arthritis : ADCs targeting specific immune cells or inflammatory mediators can provide more precise treatment options with potentially fewer side effects. Obesity : By targeting adipose tissue or specific metabolic pathways, ADCs could offer new treatments for obesity and related metabolic disorders.

Therapies 117

Therapies Pharmaceutical Companies Disease Treatment 117

Antidote

JANUARY 3, 2024

While the primary goal of clinical trials is to help identify potential new treatments that improve people's health and save lives, it's the unfortunate truth that the patient experience is often not prioritized.

Clinical Trials 52

Clinical Trials Trials Pharmaceutical Companies Pharmaceuticals 52

The Pharma Data

OCTOBER 9, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. 2 PsA can be a challenging disease to treat especially in younger populations, reinforcing the need for additional treatment options. A decision from the U.S.

FDA Approval 52

FDA Approval Treatment FDA Pharmaceutical Companies 52

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 71

Drug Development Metabolic Stability Clinical Trials Drugs 71

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. ERLEADA ® is an androgen receptor (AR) inhibitor indicated for the treatment of patients with nmCRPC and for the treatment of patients with mCSPC. 10 months. [5]

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

H1 Blog

JULY 24, 2023

How do pharmaceutical companies work with payers? In this blog post, we’ll take a closer look at how payer trends can reveal insights into the way patients use their medications – and how pharmaceutical companies can use this data to help improve patient outcomes.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Pharmacy 52

DrugBank

MARCH 15, 2024

The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity.   Mounjaro received approval as a treatment for diabetes in 2022, then in late 2023, under the brand name Zepbound (tirzepatide), it was approved for weight loss. With sales soaring to $2.2

Pharmaceutical Companies 68

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 68

The Pharma Data

MAY 27, 2022

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response . to develop and commercialise cilta-cel.[1].

Therapies 52

Therapies Treatment Pharmaceutical Companies Nurses 52

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

AUGUST 19, 2020

August 19, 2020 – Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 NEW BRUNSWICK, N.J.,

Disease 52

Disease Pharmaceuticals Treatment Pharmaceutical Companies 52

H1 Blog

DECEMBER 4, 2023

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. With the rise of digital health and data, there are endless possibilities for reaching vulnerable populations and improving access to treatment.

Clinical Trials 59

Clinical Trials Trials Pharmaceutical Companies Drug Development 59

The Pharma Data

NOVEMBER 8, 2020

FDA Approves Sesquient (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients. PAOLI, Pa., — (BUSINESS WIRE) — November 9, 2020 – Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. About Sedor Pharmaceuticals, LLC.

FDA Approval 52

FDA Approval FDA Long-Term Care Facilities Treatment 52

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

The Pharma Data

OCTOBER 9, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the U.S. The committee also voted unanimously to recommend use of maribavir for the treatment of refractory CMV infection and disease without genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

FDA 52

FDA Treatment Disease Pharmaceutical Companies 52

Altus Drug Development

JUNE 30, 2022

A focus on customers has always been one of the main pillars of the pharmaceutical industry. While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. The onset of the covid-19 pandemic has caused considerable strain on the pharmaceutical industry as a whole.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

The Pharma Data

MARCH 26, 2021

Despite continuous innovations in the treatment landscape, unmet needs remain. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. vs. 9.4%), nasopharyngitis (19.3%

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

The Pharma Data

JANUARY 15, 2021

January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. The study evaluated Darzalex Faspro® in combination with VCd, compared with VCd alone, a common treatment regimen used in adult patients with newly diagnosed AL amyloidosis.[5] Comenzo, M.D., Director, John C.

FDA Approval 52

FDA Approval Treatment FDA Pharmaceutical Companies 52

Advarra

APRIL 4, 2024

In the realm of pharmaceutical development, ensuring the safety and efficacy of new treatments is paramount. Traditionally, pharmaceutical sponsors have formed a new DSMB for each individual trial.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials FDA 52

Drug Target Review

OCTOBER 14, 2024

who shared his thoughts on the challenges faced by biotech companies in drug discovery, highlighting the critical role of data and technology in overcoming inefficiencies in the pharmaceutical industry. We interviewed Dr Neil Wilkie, CEO of Mironid Ltd.,

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.

Drug Development 81

Drug Development Clinical Trials Drugs Therapies 81

The Pharma Data

APRIL 19, 2022

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia.

Pharmaceutical Companies 52

Pharmaceutical Companies Compliance Biosimilars Pharmaceuticals 52

The Pharma Data

AUGUST 19, 2020

19, 2020 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 NEW BRUNSWICK, N.J. ,

Disease 40

Disease Pharmaceuticals Treatment Pharmaceutical Companies 40

The Pharma Data

NOVEMBER 23, 2021

Today’s approval helps meet a significant unmet medical need by providing a treatment option for this patient population.”. In the study, 352 transplant recipients with CMV infections who did not respond (with or without resistance) to treatment randomly received Livtencity or treatment assigned by a researcher for up to eight weeks.

FDA Approval 52

FDA Approval Treatment FDA DNA 52

The Pharma Data

FEBRUARY 1, 2021

Medical professionals are desperately seeking effective treatments as hospitals are continuously overwhelmed with COVID-19 patients. One recently introduced, promising COVID-19 treatment is produced from the antibodies in the plasma of recently recovered virus patients.

Treatment 52

Treatment Virus Hospitals Pharmaceutical Companies 52

The Pharma Data

APRIL 4, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA ® (apalutamide) in the United States. Each person and their cancer are unique and, as such, there is no one-size-fits-all approach to treatment,” said Luca Dezzani, M.D.,

Specialty Pharmacies 40

Specialty Pharmacies FDA Approval Pharmaceutical Companies Pharmacy 40

The Pharma Data

AUGUST 18, 2020

Johnson & Johnson statement on the launch of new CARE (Corona Accelerated R&D in Europe) consortium, Europe’s largest, multi-partner scientific research initiative dedicated to discovering and developing urgently needed treatment options for COVID-19. The reader is cautioned not to rely on these forward-looking statements.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

MARCH 15, 2022

For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections , Inc. to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience. John Reed , MD , Ph.

Science 52

Science Treatment Clinical Trials Therapies 52

PPD

JUNE 20, 2024

Acceleration in every step of clinical research is critical to pharmaceutical developers. Despite advances in technology and innovation, pharmaceutical leaders say that trials are increasingly complex, particularly when it comes to patient recruitment and site engagement.

Clinical Research 52

Clinical Research Research Clinical Trials Pharmaceuticals 52

The Pharma Data

APRIL 27, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that that the U.S. FDA granted mobocertinib Orphan Drug Designation for the treatment of lung cancer with HER2 mutations or EGFR mutations including Exon20 insertion mutations. About Takeda Pharmaceutical Company Limited.

FDA 52

FDA Treatment Pharmaceutical Companies Therapies 52

The Pharma Data

DECEMBER 3, 2020

The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e.,

Treatment 52

Treatment Pharmaceutical Companies Therapies Virus 52

PPD

NOVEMBER 11, 2024

However, getting essential treatments to patients quickly and safely requires more than just technological innovation. A global network with local expertise To ensure the delivery of treatments to patients worldwide, biotech and biopharma companies also need partners that can provide comprehensive solutions from a geographic perspective.

Drug Development 52

Drug Development Clinical Trials Drugs Small Molecule 52

The Pharma Data

APRIL 16, 2021

Opdivo in combination with Cabometyx was generally well tolerated, with a low rate of treatment-related discontinuations. The combination of Opdivo and Cabometyx was well tolerated, with safety reflective of the known profiles of both medicines and a low rate of treatment-related adverse events (TRAEs) leading to discontinuation.

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

DrugBank

SEPTEMBER 19, 2024

Oral drug delivery remains the gold standard in pharmaceutical administration. It offers convenience for patients, promotes medication adherence, and improves treatment outcomes. This could aid in treatment for diabetic patients who currently rely on injections. This knowledge is instrumental in optimizing treatment plans.

Pharmacokinetics 82

Pharmacokinetics Drugs Treatment Disease 82